Repurposing the hypoglycaemic agents for neuroinflammation, a comprehensive review
Abstract
The shared pathways between neuroinflammation and diabetes mellitus involve the NLRP3 inflammasome and subsequent production of the IL-1β. Chronic hyperactivation of hypothalamo-pituitary-adrenal axis and innate immunity are implicated in neurological disorders and diabetes. Repurposing drugs with anti-inflammatory properties allows for faster clinical translation in neuroinflammation as compared to developing new drugs from scratch. Few repurposed drugs have already undergone safety and efficacy testing for other conditions, making them attractive candidates for the neuroinflammatory disorders. Gliburide, an oral hypoglycaemic effectively inhibits the NLRP3 inflammasome, signifying that it may be used to treat the neuroinflammation-related disorders. A GLP-1 receptor agonist, liraglutide established encouraging effects in regulating hyperglycaemia and possibly lowering neuroinflammation. Patients who were obese and receiving liraglutide saw improvements in their glycaemic control and a decrease in neuroinflammatory markers in addition to the weight loss. Studies on mice suggested that, sulphonyl-ureas have properties to decrease the neuroinflammatory conditions and has potential benefits by targeting the NLRP3 inflammasome pathway, modulating lipopolysaccharide induced micro and astroglial neuroinflammation by activating the ERK/STAT3/NF-κB signalling pathways. Empagliflozin offered neuroprotection and helped in neurovascular remodelling, which is crucial for maintaining…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.